Australia's Memphasys surges on commercialisation deal in Vietnam

Memphasys

01/06/2026 05:07

** Shares of Memphasys MEM.AX rise as much as 40% to A$0.007, their largest intraday pct jump since early February
** Reproductive biotech firm enters into an exclusive commercialization agreement with TMSC Viet Nam Medical Technology for the Felix system
** Felix system is a bio-separation technology that isolates the most viable sperm cells for human-assisted reproduction
** Says two-year contract valued at A$530,000 ($380,434.00)
** Adds Felix Vietnam registration expected in August 2026, after which sales can commence
** Around 10.3 million shares change hands, 4 times the 30-day average
** Stock down 21.4% YTD, including the day's moves
     
($1 = 1.3931 Australian dollars)

(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))